Sting activating nanovaccine for immunotherapy

US11376324B2 · kind B2 · utility

Assignee

• The Board of Regents of the University of Texas System · US

Inventors

• Jinming Gao · Dallas, US
• Zhijian Chen · Dallas, US
• Min Luo · Beijing, CN
• Zhaohui Wang · Chapel Hill, US
• Hua Wang · Columbus, US
• Haocheng Cai · Dallas, US
• Gang Huang · Nanhu, CN
• Yang-Xin Fu · Zhejiang, CN

Key dates

• Filing date: Mar 2, 2017
• Grant date: Jul 5, 2022
• Expiry date: Mar 6, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In some aspects, the present disclosure provides vaccine compositions comprising an antigen and a diblock copolymer wherein the diblock copolymer is pH responsive. In some embodiments, these compositions activate the STING and/or the interferon receptor pathways. In some embodiments, the diblock copolymer hits a pKa from about 6 to about 7.5. Also provided herein are methods of treatment using these compositions to treat an infectious disease or cancer.